Enliven Therapeutics (ELVN) Total Liabilities (2019 - 2026)
Enliven Therapeutics (ELVN) posted Total Liabilities of $11.5 million for Q1 2026, down 30.67% sequentially from $16.6 million in Q4 2025, and down 19.53% YoY from $14.3 million in Q1 2025.
Enliven Therapeutics (ELVN) Total Liabilities (2019 - 2026) Analysis & Trends
Enliven Therapeutics has reported Total Liabilities for 8 years, with the latest figure at $11.5 million in Q1 2026.
- Quarterly Total Liabilities fell 19.53% year-over-year to $11.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.5 million (down 19.53% YoY) and the FY2025 annual result came in at $16.6 million, up 4.1% from the prior year.
- Total Liabilities slipped to $11.5 million in Q1 2026 per ELVN's latest filing, from $16.6 million in the prior quarter.
- Over five years, Total Liabilities peaked at $26.0 million in Q4 2023 and troughed at $1.8 million in Q3 2022.
- A 5-year average of $13.9 million and a median of $14.3 million in 2025 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2022 and 2023: Total Liabilities slumped 76.25% in 2022, then surged 576.18% in 2023.
- Over 5 years, Total Liabilities stood at $10.4 million in 2022, then soared by 150.25% to $26.0 million in 2023, then plunged by 38.7% to $15.9 million in 2024, then grew by 4.1% to $16.6 million in 2025, then sank by 30.67% to $11.5 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $11.5 million, $16.6 million, and $14.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Enliven Therapeutics | 4.31 Bn | 3.41 Bn | - | 15.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.07 Mn |
| Mar 31, 2026 | 11.49 Mn |
| Dec 31, 2025 | 16.57 Mn |
| Sep 30, 2025 | 14.75 Mn |
| Jun 30, 2025 | 15.42 Mn |
| Mar 31, 2025 | 14.27 Mn |
| Dec 31, 2024 | 15.92 Mn |
| Sep 30, 2024 | 17.03 Mn |
| Jun 30, 2024 | 22.11 Mn |
| Mar 31, 2024 | 25.07 Mn |
| Dec 31, 2023 | 25.96 Mn |
| Sep 30, 2023 | 12.29 Mn |
| Jun 30, 2023 | 9.51 Mn |
| Mar 31, 2023 | 11.45 Mn |
| Dec 31, 2022 | 10.37 Mn |
| Sep 30, 2022 | 1.82 Mn |
| Jun 30, 2022 | 3.30 Mn |
| Mar 31, 2022 | 9.19 Mn |
| Dec 31, 2021 | 7.62 Mn |
| Sep 30, 2021 | 7.65 Mn |